ArticlePharmaceutical research2014
Insight into mechanisms of cellular uptake of lipid nanoparticles and intracellular release of small RNAs.
Article in Pharmaceutical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 70 citations in OpenAlex.
- Article
- Pulmonary Delivery of siRNA Anti-TNFα-loaded Lipid Nanoparticles for Rapid Recovery in Murine Acute Lung Injury.Advanced healthcare materials · 2025Article
- The Internal Nanostructure of Lipid Nanoparticles Influences Their Diverse Cellular Uptake Pathways.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Targeting and tracking mRNA lipid nanoparticles at the particle, transcript and protein level.Nature biomedical engineering · 2025Review
- Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics.ACS nano · 2025Article
- Immunogenicity and protective efficacy of the HC009 mRNA vaccine against SARS-CoV-2.Frontiers in immunology · 2024Article
- Ferric-loaded lipid nanoparticles inducing ferroptosis-like cell death for antibacterial wound healing.Drug delivery · 2023Article
- Article
- Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy.Acta pharmaceutica Sinica. B · 2023Article
- Antitumor Activity of Anti-miR-21 Delivered through Lipid Nanoparticles.Advanced healthcare materials · 2023Article
- Advances of Electroporation-Related Therapies and the Synergy with Immunotherapy in Cancer Treatment.Vaccines · 2022Review
- CD73 downregulation by EGFR-targeted liposomal CD73 siRNA potentiates antitumor effect of liposomal doxorubicin in 4T1 tumor-bearing mice.Scientific reports · 2022Article
- Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy.Molecules (Basel, Switzerland) · 2022Review
- Innovations in Biomaterial Design toward Successful RNA Interference Therapy for Cancer Treatment.Advanced healthcare materials · 2021Review
- Recent advances in siRNA delivery mediated by lipid-based nanoparticles.Advanced drug delivery reviews · 2020Review
- A Review on Electroporation-Based Intracellular Delivery.Molecules (Basel, Switzerland) · 2018Review
- Microfluidic-Based Single-Cell Study: Current Status and Future Perspective.Molecules (Basel, Switzerland) · 2018Review
- Microfluidic hydrodynamic focusing synthesis of polymer-lipid nanoparticles for siRNA delivery.Oncotarget · 2017Article
- Evaluation of antitumor activity of survivin short interfering RNA delivered by lipid nanoparticles in colon cancerOncology letters · 2017Article
- Delivery System of CpG Oligodeoxynucleotides through Eliciting an Effective T cell Immune Response against Melanoma in Mice.Journal of Cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeUnderstanding mechanisms of cellular uptake and intracellular release would enable better design of nanocarriers for delivery of nucleic acids such as siRNA and microRNA (miRNA).
methodIn this study, we investigated cellular pharmacokinetics of siRNA by co-encapsulating fluorescently labeled siRNA and molecular beacon (MB) in four different formulations of cationic lipid nanoparticles (LNPs). A miRNA mimic was also used as a probe for investigating cellular pharmacokinetics, which correlated well with RNAi activities.
resultsWe tried to find the best LNP formulation based on the combination of DOTMA and DODMA. When the DOTMA/DODMA ratio was at 5/40, the LNP containing a luciferase siRNA produced the highest gene silencing activity. The superior potency of DOTMA/DODMA could be attributed to higher uptake and improved ability to facilitate siRNA release from endosomes subsequent to uptake.
conclusionsOur findings may provide new insights into RNAi transfection pathways and have implications on cationic LNP design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.